<html xmlns="http://www.w3.org/1999/xhtml"><head>
        <meta http-equiv="Content-Type" content="text/html; charset=utf-8">
        <meta name="viewport" content="width=device-width, height=device-height, initial-scale=0.5, minimum-scale=0.5, user-scalable=yes, maximum-scale=2.0, target-densitydpi=device-dpi" />
				<meta name="robots" content="all"/>
        <meta name="description" content="description">
        <meta name="keywords" content="">
        <title>Page 376 - MIMS April 2020 E4</title>
<style type="text/css">
<!--
body {
	margin-left: 0px;
	margin-top: 0px;
	margin-right: 0px;
	margin-bottom: 0px;
}
  
#container {margin:50px auto;padding:0px;width:910px;}
#left-button{ width:90px; height:100%;float:left }
#middle{ width:730px; margin:0px; float: left;}
#right-button{ width:90px; float:left;}
html, body, div, ul, li, dl, dt, dd, h1, h2, h3, h4, h5, h6, form, input, dd,select, button, textarea, iframe, table, th, td { margin: 0; padding: 0; }
img { border: 0 none; displayblock}
span,ul,li,image{ padding:0px; margin:0px; list-style:none;}
#top-title{ width:714px; margin-bottom:10px; float:left; padding:0px 8px}
#top-title2{ width:320px;  float:right;}
#content{ width: 730px; float:left;float:left;word-wrap: break-word;}
#content-top{ width:730px; background-image:url(images/top_bg.jpg); height:56px; background-repeat:no-repeat; float:left;}
#content-top1{ width:70%; padding:16px 0px 0px 30px; font-family:Arial, Helvetica, sans-serif; font-size:24px; color:#636363;float:left;}
#content-top2{ width:60px; float:right; padding:25px 30px 0px 0px;font-family:Arial, Helvetica, sans-serif; font-size:11px; color:#2f2f2f; font-weight:bold; text-align:right}
#content-middle{ width:730px; background-image:url(images/middle_bg.jpg); background-repeat:repeat-y;float:left;}
#content-middle1{ width:475px; padding:25px 0px 25px 35px; font-family:Arial, Helvetica, sans-serif; font-size:12px; color:#636363; line-height:150%;float:left;}
#content-middle2{  padding:7px; float:right; margin:25px 35px 0px 0px; border:solid 1px #c8c8c9; background-color:#FFF; text-align:center}
#content-bottom{ width:730px; background-image:url(images/bottom_bg.jpg); background-repeat:no-repeat; height:58px;float:left;}
#content-bottom2{ width:110px; height:42px; margin:0px auto; padding-top:4px;}
#input{ width:58px; height:20px; background-color:#FFF; border:solid 1px #dfdfe0; color:#636363; text-align:center; font-size:11px;}
.font1{ font-family:Arial, Helvetica, sans-serif; font-size:10px; color:#2f2f2f;}
.font1 a:link{
	text-decoration: none;
    color:#2f2f2f;

}
.font1 a:visited{
	text-decoration: none;
    color:#2f2f2f;
	
}
.font1 a:hover{
	color: #2f2f2f;
	text-decoration: underline;

}



.text-container {
padding: 20px;
color: #333;
margin-top: 24px;
line-height: 22px;
border-top-left-radius: 3px;
border-top-right-radius: 3px;
}

.use-as-video {
float: right;
padding-left: 20px;
}
.cc-float-fix:before, .cc-float-fix:after {
content: "";
line-height: 0;
height: 0;
width: 0;
display: block;
visibility: hidden;
}
.use-as-video-img {
cursor: pointer;
position: relative;
width: 320px;
height: 180px;
}
.use-as-video-title {
font-size: 15px;
font-weight: bold;
color: #000000;
padding-bottom: 5px;
}
-->
</style>
<script type="text/javascript">
<!--
function MM_preloadImages() { //v3.0
  var d=document; if(d.images){ if(!d.MM_p) d.MM_p=new Array();
    var i,j=d.MM_p.length,a=MM_preloadImages.arguments; for(i=0; i<a.length; i++)
    if (a[i].indexOf("#")!=0){ d.MM_p[j]=new Image; d.MM_p[j++].src=a[i];}}
}

function MM_swapImgRestore() { //v3.0
  var i,x,a=document.MM_sr; for(i=0;a&&i<a.length&&(x=a[i])&&x.oSrc;i++) x.src=x.oSrc;
}

function MM_findObj(n, d) { //v4.01
  var p,i,x;  if(!d) d=document; if((p=n.indexOf("?"))>0&&parent.frames.length) {
    d=parent.frames[n.substring(p+1)].document; n=n.substring(0,p);}
  if(!(x=d[n])&&d.all) x=d.all[n]; for (i=0;!x&&i<d.forms.length;i++) x=d.forms[i][n];
  for(i=0;!x&&d.layers&&i<d.layers.length;i++) x=MM_findObj(n,d.layers[i].document);
  if(!x && d.getElementById) x=d.getElementById(n); return x;
}

function MM_swapImage() { //v3.0
  var i,j=0,x,a=MM_swapImage.arguments; document.MM_sr=new Array; for(i=0;i<(a.length-2);i+=3)
   if ((x=MM_findObj(a[i]))!=null){document.MM_sr[j++]=x; if(!x.oSrc) x.oSrc=x.src; x.src=a[i+2];}
}
//-->
</script>
</head>

<body onload="MM_preloadImages('images/next2.png','images/previous2.png')">
<div id="container">
<div id="left-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page375.html"><img src="images/previous_big.png" width="90" height="80" /></a></p>
</div>
<div id="middle">
  <div id="top-title"><span class="font1">Basic HTML Version</span>
    <div id="top-title2">
      <table width="100%" border="0" align="right" cellpadding="0" cellspacing="0">
        <tr>
        	<td width="66%"> </td>
          <td width="35%" style="display:none" align="right"><img src="images/content.png" width="19" height="16" /></td>
          <td width="31%" style="display:none" class="font1"><a href="">Table of Contents</a></td>
          <td width="6%"><img src="images/view.png" width="19" height="16" /></td>
          <td width="28%" class="font1"><a href="../../MIMS April 2020 E4.html#p=376">View Full Version</a></td>
        </tr>
      </table>
    </div>
  </div>
  <div id="content">
     <div id="content-top">
        <div id="content-top1">Page 376 - MIMS April 2020 E4</div>
        <div id="content-top2">P. 376</div>
     </div>
     <div id="content-middle">
     	
     	  <div class="text-container">
    <div class="use-as-video cc-float-fix">
      <a style="text-decoration: none;" href="../../MIMS April 2020 E4.html#p=376"><img src="../thumb/376.jpg" /></a>
    </div>

    <p class="use-as-video-title"></p>
    <pre style="white-space:pre-line"><code>Biologicals - 26                                                               2020-04 / 339
          3.0
       than 10  CCID 50; Mumps virus of RIT 4385 strain derv.from Jeryl   Contraindications: No absol.contraindicat.to admin. of rabies im-  (S2) SOL, A 40/30.1/0730
       Lynn strain not less than 10  CCID 50, rubella virus of Wistar RA 27/3   munoglob.because of life-threaten. risk assoc.with rabies, pts.with   710935-001: Sngl.pre-fill.unit dos, 2 ml, R263,99
                  4.4
       strain not less than 10  CCID 50, varicella virus of OKA strain not less   proven immunity to rabies.  Dosage: Oral admin.only to infts.6 wks.to 32 wks. Vaccinat.consists
                3.0
       than 10  PFU /0,5 ml.         Side effects: Loc./ anaphylact.reacts., fev., headache, chills, flush.,   of 3x ready to use liq. dos. Do not mix.with other vacc./sols. Do not
          3.3
       Indications: Activ.immunisat. from 9 mnths. up to 12 yrs. against   lightheadedn., backache, naus., IgA sensitisat., imp.effic.of live at-  reconstit./dil. No restrict.on inft.food/liq.consumpt. Admin.to pre-term
       measles, mumps, rubella & varicella.  tenuat. virus vacc.  infts.accord.to chronolog.age. Replacem. dos. not indicat.if inft.spits/
       716550-001: 1xmonodos.vial+dil., R574,25  Special precautions: Consid.immunit.weigh risk-benef. ratio of pts.  regurgit.vacc.aft. admin. Compl.course.
                                                                   st
       Dosage: For SC inj., pref.in.outer aspect of upper arm. Allow disin-  with IgA defic.hist.or sev. anaphylact. reacts.to plasma products, not   1  dos: Admin.at 6-12 wks. Subseq.dos: Admin. at minim.interv.
       fect.agent to evapor. bef. admin.  for IV admin., delay live virus vaccinat.for 3 mnths.aft. treatm.,pregn.&   of 4 wks.betw.dos.
       Pts.from 9 mnths. - 12 yrs should rec. 2 dos.of PRIORIX TETRA to   lactat., lab.diagnos.not to delay treatm. init., consid.halt.treatm.if no   Contraindicatons: Not for inj., safety & effic.not est.in infts. less
       ensure optimal protect. Respect interv. &gt; 6 wks betw. doses. Interv.  rabies virus detect. in offend.anim., if treatm.delay.admin. immono-  than 6 wks., insuff.data for admin.to infts.with indeterm.HIV status
       should under no circumst. be &lt; 4 wks.  Alternat. & in accord.with   globul. up to 7  day aft.first vacc.dos., rep. dos. not be admin.once   or born to mothers with HIV/AIDS, adults, no safety/effic. data avail.
                                           th
       offic. recommendat.a sngl.dos.of PRIORIX TETRA may be admin.to   rabies vacc.treatm.init., infect. dis.transmiss.cannot be total.excl.,   for immunocomprom.-/HIV infect.pts or pts.receiv.bld. transfus. or bld.
       childr.who has already receiv.a sngl. dos.of another MMR vaccine   consid. appropr. vaccinat.in pts.receiv.bld./plasma prods., transit. rise   prod. incl. immunoglobul. within 42 days, rare heredit. fruct. intol./
       &/or a sngl. dos.of another varicella vacc.; a sngl.dose of PRIORIX   of var.passiv.transfer.antibod.in pts.bld aft.inj. of immunoglobul.may   gluc.-galact.malabsorpt. & sucrose-isomaltase insuffic.
       TETRA may be admin.follow.by a sngl.dos. of another MMR vacc.&/  result in mislead. positiv. results in serologic.test., admin. immuno-  Side effects: Kawasaki’s dis., nasopharyngit., diarrh., vomit., pyrex.,
       or a sngl.dos. of another varicella vacc.  glob. & vacc.at two diff.sites of body using diff. syr.to avoid interf.  otit.med., bronchosp., urticar.
       Contraindications: Act.untreat.TB, bld. dyscras, leukaem., lym-  with activ.antibody respon., admin.in.div.dos.at diff.sites if large vol.   Special precautions: Cons.benef./risk in infts. with ser.med.con-
       phomas of any type, malign neoplasma affect.bone marr./lymphat.  (&gt;2 ml for childr./ &gt;5 ml for adults) reqd., do not mix with other prods.  dits., obt.med.hist.to excl.prev. vaccin.undesir.effs., no re-challenge
       syst., neomycin hypersens., imp.immune respons., humoral/ cellul   if hypersens. sympt.aft.admin., immune respons.poss.reduc.with
       (prim/acquir.) immunodefic., pregn., intravascul.admin., hypersens.  RHESUGAM IM, NBI [P/S]  concom.OPV, act.GI illn., chron.diarrh., growth retardat., congen.ab-
       aft.prev. admin. of measles, mumps, rubella &/or varicella vacc.,   Human anti-D immunoglobul.deriv.from pool. human plasma from   dom.disords., intussuscept., poss. delay vacc.in case of ac.infect./
       PRIORIX TETRA: intraderm. admin  Rh 0-negat.donors sensitis.to Rh 0(D) antigen, test.& found non-react.  febr.illn., complete protect.of all receipt.may not result, immuno-
       Side effects: Very comm: Redn.at inj.site, fev.&gt;38°C (rectal)/&gt;37,5°C   to HBsAg & antibodies to HCV, HIV-1 & HIV-2 viruses.  defic.close contacts.
       (axillary/oral). Comm: URTI, rash, inj.site pain/swell., fev.&gt;39,5 C (rec-  Indications: Rh o sensitisat.prophylax.
       tal)/&gt;39 °C (axillary/oral). Uncomm: Otit.med., lymphadenopathy, an-  (S4) IM INJ. T/30.2/750. 100 µg or 500 IU/2 ml  ROUVAX, Sanofi Aventis [P/S]
       orex., nervousn., abnorm.cry, insomn., conjunctivit., bronchit., cough,   810509-008: Sngl.amps, R759,17  Live attenuat.measles virus (Schwarz strain) cultiv. in chick embryo
       parotid gland enlargem., diarrh., vomit. Rare: Allerg. reacts., febr.  Dosage: Admin.IMI as soon as poss., but always within 72 hrs.of   tiss. Neomycin traces.
       convuls., meningit., measles & mumps-like syndr.,thrombocytopen.,   poss.sensitis.event.   Indications: Act.measles immunisat.
       thrombocytopen. purpura, anaphylact.reacts., encephalit., cerebellit.,   Antenat.prophylax: Recomm.dos: Admin.500 IU (100 µg ) at 28   (S2) INJ. T/30.1/688. 1 000 TCID  50/0,5 ml.
       Guillain Barré syndr., transv. myelit., periph.neurit., vasculit., erythema   and/34 wks. gest. If inft.is Rh o pos., a simil./high.dos.recomm.aft.deliv.  825522-005: sngl.dos.prefill.syr, R152,21
       multiforme, arthralg., arthrit.  Prophylax.aft.potent.sensitis.events: Recomm. dos: 250 IU (50µg)   Dosage: Optim.age 9 mnths with booster at 18 mnths. Addit.dos.
       Warnings and special precautions: Postpone vaccinat. dur.  for events up to 20 wks. whereaft. dos.of 500 IU (100µg) is recomm.  at 6 mnths.of age recomm.for HIV posit.pts. May be admin.at same
       ac. sev.febrile illn., defer for 3 mnths. follow. plasma/bld.transfus./  Postnat.prophylax: Recomm.dos: 500 IU (100µg)  time as other vacc.(see lit.)
       human immune ser. globulin admin, avoid pregn.x1 mnth.aft.vacc.,   Transfus.of Rh incompat.blood: Admin.125 IU (25 µg) for each   0,5 ml by SC/IM inj. Childr.und.1 yr: will require booster 6 mnths.later.
       women intend.pregn.to delay pregn., consid.risk vs.benef.in lactat.,   1 ml of red cells.  Contraindications: Act./develop.ac.resp.infect., act.untreat.TB, im-
       post vaccinat.meningit.report. with mumps vir.vacc., topic.alcohol &   Transfus.of Rh o pos.platel.in Rh o neg.wom.of child-bear.age:   muno-comprom.pts., pregn., vaccinat.within 6 wks.& pref.not within
       other disinfect. will inactiv.attenuat.virus., limit.measle protect.obt.  Admin.250 IU (50 µg) for each dos.of platel.(i.e.5-6 units). If more than   3 mnths. follow.immunoglobul./bld.prod.contain. immunoglobul., egg
       with vaccinat.within 72 hrs.of natur. expos., vaccinat.of infts.und.1   10 units are used, admin.500 IU (100 µg).  prot./neomycin allergy, postpone vaccin.in case of ac.dis./fev.or pro-
       yr.may be consid.in high risk areas.but re-vaccinat.to be consid.at 12   Contraindications: Admin.to the baby, Rh o(+) mother, Rh o(–) moth-  gress. chron.dis., congenit./acquir.immunodefic., delay x3 mnths.aft.
       mnths.or aft., convuls.-/febril.convul./allerg. dis. hist./fam.hist., avoid   er given birth to Rh o(–) inft., Rh o(–) mother already having anti-D   end of immunosuppress.treatm., intravasc. admin.
       tuberculin test.for 4-6 wks. aft. vaccinat., can be giv.at same time as   antibod., IV admin.  Side effects: Hypertherm., rhinopharyng./resp. sympts., skin reacts.,
       hexaval. vacc. /Hib DTPa/DTPa/Hib/IPV/HBV/HAV/MenB/ MenC/  Side effects: Loc./allerg./anaphylact.reacts., headache, fev., chills,   adenopathy, ac. thrombocytopen. purpura
       MenACWY/PCV, gen.accept.that Priorix may be admin.at same time   flush., lightheadedn., backache, N&V., hypotens., tachycard., shock,   Special precautions: Allerg.condit., convuls. hist.in childr.postpone
       as oral polio vacc./inj. DTP vacc, use separat.sites if admin.at same   IgA sensitisat., imp.effic.of live attenuat.vir.vacc.  vaccinat.until aged 2 yrs, avoid contact.with disinfects.as they inactiv.
       time as anoth.inj.vacc., allow 1 mnth betw.other live attenuat. vacc.  Special precautions: Weigh risk-benefit ratio of pts.with IgA defic.   vacc., allow swab.skin to dry bef.admin., observe 2 wk. interv.aft.im-
       if not admin.at same time, delay. vaccinat. x3 mnths.in case of hu-  hist. or sev.anaphylact.reacts.to plasma products, IM inj.not advoc.in   munoglobul.admin., observe 3 wk. delay betw.admin.of live attenuat.
       man gammaglobul. admin./ bld.transfus.due to poss. passively acquir.   bleed. disords., delay live virus vaccinat. for 3 mnths., admin. in div.  vacc.if not admin. concom., false negat.tubercul.tests report., keep
       antibod., poss.egg trace prot.theref.pers.with anaphylact. hist./other   dos.at diff.sites if large vol. (&gt;2 ml for childr./ &gt;5 ml for adults) reqd.,   adrenaline avail.in case of anaphylact.reacts.
       immed.reacts.subseq.to egg ingest.poss.at enhanc.risk of immed.-  do not mix with other prods., infect.dis.transmiss.cannot be tot. excl.,   STAMARIL, Sanofi Aventis [P/S]
       type hypersens. reacts., ensure proced.in place to avoid injury from   consid.appropr. vaccinat.in pts.receiv.bld./ plasma prods., monit.hae-  Live attenuat.yellow fev. vir.(strain 17D-204), produc.in specif.patho-
       faint.as syncope.poss., appropr. medic. treatm.to be avail.in case of   molyt.react.risk in pts. receiv. incompat.transfus.receiv.very large dos.  gen.free chick embryo’s.
       anaphylax., a protect. immune respon.may not be elicit.in all vaccin-  of anti-D immunoglob.  Indications: Yellow fev.prophylax., act.yellow fev. immunisat.for
       ees, eval. risk-benef.in thrombocytop.aft.1st dos.as worsen./ recurr.  Warnings: Ineffect.once mother has form.anti-D antibod.  indiv.over 9 mnths liv/travell. through endem.areas, non-vaccin.peo-
       poss., immunocompromis.pts., lact. intol., contains lactose & impact.  ple mov.from an endem.to a potent.recept.non-endem.area, laborat.
       diab. glycaem.contr., SC admin.in pts.with bleed.disords. PRIORIX   ROTARIX LIQUID ORAL VACCINE, GSK [P/S]  work.handl.infect.mat.
       TETRA: incr.risk of fev.& febr.convuls.5-12 days aft.1st dos.compar.  Live attenuat.human rotavirus RIX414 strain  (S4) INJ. 27/30.1/0532. 1 000 LD 50 units/ dos.(0,5 ml).
       to 2 separate inj.of MMR & varicella vacc, avoid salicylat.for 6 wks   Indications: Prev.of gastro-enterit.caus.by Rotavirus.in infts.in   814989-004: Sngl.dos.amp.+dil., R338,43
       aft.each vaccinat. as Reye’s syndr.poss.  first 6 mths.of life  Dosage: Certific.valid for 10 yrs.from 10  day aft. vaccinat. Sched.
                                                                                   th
       Interactions: Live measle & poss.mump vaccinat. may depress.  (S2) LIQ ORAL SUSPENSION, 43/30.2/0290  identic.for adults & childr.over 9 mnths. Do not inj.intravasc. Perform.
       tubercul.skin sensitiv.       714133-001: 10  CCID 50, 1+dil., R434,06  tol.test.in allerg. indiv. Admin.other simultan.vacc.at separ. site. Do
                                           6,0
       PULMOZYME, Roche [P/S]        Dosage: Oral admin.only. Vaccine supplied ready to use. No recon-  not mix.with other vaccine in same syringe
       rhDNase=dornase alfa.         stit.or dilut.reqd. Do not mix. with other vacc./sols. Inft.to be in reclin.   Prim.immunisat: Sngl.0,5 ml IM/SC inj.of reconstit. vacc.
       Indications: Managem.of cystic fibros.pts.over 5 yrs.with a FVC   posit. and admin.towards.inner cheek.  Booster: Every 10 yrs.if expos.maint.
       &gt;40% of predict.value.        Course consists of 2 dos. 1 st dos.from the age of 6 wks. Interv. betw.  Contraindications: Congenit./acquir. immunodepress. incl.curr.
                                                                                          3
       (S3) INHAL.SOL. 28/30.4/0675. 2,5 mg/2,5 ml.  dos.not less than 4 wks. Course to be compl.by 24 wks.  supress.ther., symptomat. HIV posit.indiv./CD4&lt;200/mm , asymp-
       814679-005: 30 x2,5 ml sngl.use amps., R10 121,78  If inft. spits out/ regurgit.most of vacc.dose a singl.replacem. dos.   tomat. HIV infect.with evid.of imp.immune funct., evolv.malign.dis.,
       Dosage: One unit dose amp.once dly.to CF pts. over/ equal to 5   may be giv.at same vaccinat. visit.  egg/chick.prot.allergy, sev. react.aft.prev.admin., childr.und.6 mnths.
                                                             st
       yrs. Admin.using a jet nebul./ compress.syst. Some pts.over 21 yrs.  Complet.of 2 dos.regim.strongl.recomm.in infts. receiv.a 1  dos.   due to encephalit.risk, pregn.unless clear.need.& risk vs. benef.as-
       may benefit from twice dly admin. Take every day without a break.  Contraindicatons: Do not inject., known/ suspect. immunodefic.  sess., lactat., hist.of thymus dysfunct. incl. myasth.grav./thymona &
       Contraindications: Pregn., lactat., safety & effic. in childr.und.5   but may be admin.to asymptomat. human immunodefic.vir.(HIV)   thymectomy, childr. of HIV infect.mothers, fruct.intol.
       yrs.not est.                  infect. subj., hist.of.intussuscepts., hist.of chron.GI dis. incl.uncor-  Side effects: Neurotrop.dis.clinic.pres.within 1 mnth. with high
       Side effects: Conjunctivit., dysphon., dyspn., pharyngit., laryngit.,   rect.congenit. GIT malformat.(e.g. Meckel’s diveticul.) that would   fev./headache/confus./encephalit. / encephalopathy/meningit./foc.
       rhinit., cough., dyspeps., skin rash, urticar., chest pain (pleurit./non   predispos.for intussuscept., not intend.for adult use, sev. combin.   neurologic.defic./ Guillain-Barre, viscerotrop.dis.within 10 days pres.
       card.), pyrex., poss. deteriorat.of pulm. funct.& incr.in sputum expec-  immunodefic.(SCID)  as fev./fatig./myalg./headache & hypotens. progress to metabol.
       torat., developm.of IgE antibodies to rhDNase.  Side effects: Irritabil., loss of appetite, diarrh., vomit., flatul., abdom.  acidos./musc.& liv.cytolysis/ lymphocytopen. & thrombocytopen./
       Special precautions: Do not mix with other drugs, use entire amp.  pain, gastro-enterit., intussuscept., haematochez, gastroenterit.with   ren.& resp. fail., headache, naus.& diarrh., abdom.pain, myalg., ar-
       contents at one time, containm. of aerosol not necess., pts.with se-  vacc.vir.shedd.in infts. with SCID., fev., cough, rhinorrh., dermatit.  thralg., loc.reacts., pyrex., asthen., lymphadenopathy, anaphylact.
       riously imp.pulm.funct tests and FVC &lt;40%, store in refrigerator.  Warnings and special precautions: Do not admin. to childr.old.  reacts., rash, urticar.
                                     than 24 wks.of age, in absence of loc.recomm.observ.interv.of 2 wks.
       RABIGAM IM, NBI [P/S]         betw.admin.of OPV & Rotarix, obt.med.hist.to excl. prev.vaccinat.  Special precautions: Postpone in event of fev./ ac. illn./chron.evolv.
                                                                  dis., seek spec.paed.advice for HIV infect.childr., childr.&lt;9 mnths.&
       Human rabies immunoglobulin deriv.from pooled human plasma with   undesir.events, postpone in pres. of ac.sev.febrile illn.and/or diarrh./  persons with congenit./ acquir.immunodefic.at risk of develop. yellow-
       high titre of antibodies to rabies virus, test.& found non-react.to HB-  vomit., cons. potent.benef.vs.risk caref.prior to admin.in immunosu-  fev. vacc.-assoc.neurotropic dis.within a mnth. of vaccinat., delay vac-
       sAg & antibodies to HCV, HIV-1 & HIV-2 viruses.  press. infts, safety & effic.unknown in infts. with GI illness., postmar-  cinat.till immune funct. recov.in pts.receiv.immunosuppress.treatm.,
       Indications: Post-expos.prophylax.of rabies infect.aft.known/sus-  ket.trans.incr.in intusscept. aft.vaccinat.most.within 7 days of 1  dos   allow 1 mnth. interv.aft.high dos.system. corticoster. ther.of 14 days or
                                                               st
       pect.expos.to rabies virus in conjunct. with rabies vaccine; admin.aft.  and to less with extent with 2  dos., follow-up any sympts.indicat.of   long., insuffic.data on HIV infect.persons to different.who could safely
                                                 nd
       any Cat.III expos irrespect.of interv.betw. expos.& initiat.of treatm.up   intussuscept.incl.sev. abdom. pain/persist. vomit./bldy.stool/abdom.   be vaccinat.& in whom vaccinat.could be hazard.& ineffect., seek of-
       to 7 .day aft.first dos.of vaccine giv., treat.prev. vaccine immunised   bloat./high fev., contacts to observ.person. hygiene, protect.respons.  ficial guid.to eval.potent.risks vs. benefits of vaccinat.asymptomat.
         th
       indiv.with rec.confirm.adeq.antibody titre with vaccine only.  not elicit.in all vaccinees, does not protect against other pathogens,   HIV-infect. person. if trav.unavoid., consid.control vaccinat.of child.
       (S4) IM INJ. T/30.2/748. 150 IU/ml.  breastfeed.may be contin.dur. vaccinat. sched.  betw.6-9 mnths.dur.outbreak, risk:benefit eval. in pts.&gt;60 yrs.as incr.
       731528-018: 1x2 ml amp, R834,91                            in ser.adverse effs.incl. vacc. assoc.neurotrop.dis.& viscerotrop.dis.
       Dosage: Admin.as soon as possible aft.expos. Adults & childr:   ROTATEQ, MSD [P/S]  report., thymus gland dis.potent.risk fact.for vacc.-assoc. viscerotropic
       Recomm.dos: 20 IU/kg bm admin. at same time as vaccine but at   Live pentavalent reassort.rotavirus oral vaccine. Contain.human-bo-  dis., adrenaline avail.in event of anaphylact. reacts., bleed.disords.,
       a diff.anatomic. site. Infiltr.full dos.into depth of & around wound,   vine rotavir.reassort.at follow. min.dos lev.G1: 2,2x10 , G2: 2,8x10 ,  6  concom. anticoag. ther., allerg.indiv.
                                                           6
       admin.remaind.by deep IMI at diff.site from that used for the vac-  G3: 2,2x10 , G4: 2,0x10  & P1A[8] 2,3 x10 infect.units/2 ml dos.
                                              6
                                         6
                                                      6
       cine. Ensure wound adeq.infiltrat. with immunoglobul.bef.sutur. Do   Indications: Prev.of rotavir.gastro-enterit.in infts. & childr.caus.  STELARA, Janssen Pharmaceutica (Pty) Ltd.
       not exceed recomm. dos.       by the serotypes G1, G2, G3, G4 & G-serotype cont.P1A[8](e.g.,G9).  See Section 24.1</code></pre>
     	</div>
    
     </div>
     <div id="content-bottom">
       <div id="content-bottom2">
         <table width="110" border="0" cellspacing="0" cellpadding="0">
           <tr>
             <td width="22%" height="44"><a href="page375.html"><img src="images/previous.png" width="26" height="19" id="Image2" onmouseover="MM_swapImage('Image2','','images/previous2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
             <td width="43%">
             	&nbsp;&nbsp;&nbsp;<a href="page371.html">371</a>&nbsp;&nbsp;&nbsp;<a href="page372.html">372</a>&nbsp;&nbsp;&nbsp;<a href="page373.html">373</a>&nbsp;&nbsp;&nbsp;<a href="page374.html">374</a>&nbsp;&nbsp;&nbsp;<a href="page375.html">375</a>&nbsp;&nbsp;&nbsp;<a href="page376.html">376</a>&nbsp;&nbsp;&nbsp;<a href="page377.html">377</a>&nbsp;&nbsp;&nbsp;<a href="page378.html">378</a>&nbsp;&nbsp;&nbsp;<a href="page379.html">379</a>&nbsp;&nbsp;&nbsp;<a href="page380.html">380</a>&nbsp;&nbsp;&nbsp;<a href="page381.html">381</a>
             </td>
             <td width="35%"><a href="page377.html"><img src="images/next.png" width="26" height="19" id="Image1" onmouseover="MM_swapImage('Image1','','images/next2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
           </tr>
         </table>
       </div>
     </div>
  </div>
</div>
<div id="right-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page377.html"><img src="images/next_big.png" width="90" height="80" /></a></p>
</div>


</div>

</body>
</html>
